Daa Pangenotypic Epclusa denied as not medically necessary by Humana?

Humana's specific coverage criteria for daa pangenotypic epclusa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issued a Medical-Necessity Denial for Epclusa

Epclusa (sofosbuvir/velpatasvir) is a pangenotypic direct-acting antiviral for chronic hepatitis C. Humana's medical-necessity denials for this drug typically arise when the prior-authorization submission lacks sufficient clinical detail — for example, missing genotype confirmation, fibrosis staging, or documentation of prior treatment attempts — or when the submitted information does not clearly map to the eligibility criteria in Humana's hepatitis C coverage policy.

Medical-necessity denials are among the most commonly reversed on appeal. The standard is not whether a treatment is helpful in general, but whether it is medically necessary for this specific patient. A well-documented appeal that directly addresses each criterion Humana lists almost always has a strong chance of success.

## Federal Appeal Framework

• ACA Section 2719 / external review: Non-grandfathered plans must offer independent external review by an accredited IRO after internal appeals are exhausted. The standard external-review window is approximately four months from the denial notice; confirm the exact deadline on your Explanation of Benefits. Expedited external review (roughly 72 hours) is available for urgent medical situations.
• ERISA Section 503: Employer-sponsored plans must provide a full-and-fair review, including written disclosure of the criteria applied and the right to submit additional clinical information.

## Concrete Appeal Steps and Timeline

1. Obtain the written denial notice specifying which medical-necessity criteria were not met. 2. Download Humana's current hepatitis C DAA coverage/medical policy — available through their provider portal — and identify the exact criteria that apply. 3. File a Level 1 internal appeal, typically within 180 days of denial (verify your plan document). 4. If upheld internally, file for external review within the deadline printed on the denial notice.

## Documentation to Gather

• Diagnosis confirmation: Hepatitis C genotype report, quantitative viral load, and current liver-disease staging (fibrosis or cirrhosis grading via biopsy or elastography).
• Prior-treatment history: Names, dates, and documented outcomes of any previous hepatitis C regimens, establishing treatment history relevant to Humana's step-therapy or treatment-experienced criteria.
• Clinical severity: Chart notes documenting hepatic function, comorbidities (e.g., HIV co-infection, renal status), and disease trajectory.
• Prescriber medical-necessity letter: A detailed letter from the treating provider linking the patient's specific clinical findings to each requirement in Humana's published policy and in the FDA-approved prescribing label for Epclusa.

## Criteria-Mapping Structure

From Humana's policy and the Epclusa prescribing label, list every stated requirement in a table. For each requirement, provide the corresponding chart fact — note date, lab result, or prescriber statement — that satisfies it. This side-by-side format removes ambiguity and gives the internal reviewer a clear basis for approval. Where a criterion involves professional society guidance, cite the relevant organization (e.g., the applicable AASLD/IDSA hepatitis C guidance) without quoting specific numeric thresholds from memory — direct Humana to the current published version.